Diagnosing IgG4-related disease requires a careful combination of clinical observation, blood tests, imaging studies, and tissue examination, as no single test can confirm the condition on its own. The disease often remains hidden for months or years before diagnosis, during which time organs may silently sustain damage even when patients feel relatively well.

Who Should Undergo Diagnostics and When to Seek Testing

People who should consider diagnostic evaluation for IgG4-related disease (IgG4-RD) include those experiencing unexplained swelling or enlargement of organs, particularly middle-aged to older adults. The condition predominantly affects males, who tend to experience more severe disease with involvement of multiple organs and higher levels of certain blood markers. However, anyone—from children to individuals in their nineties, regardless of race or ethnicity—can develop this condition.^[1][2]

Many patients with IgG4-RD experience no noticeable symptoms for extended periods, which means the disease can cause organ damage while a person feels well, long before they seek medical attention. This silent progression makes it particularly important to investigate when certain warning signs appear. You should seek diagnostic evaluation if you notice painless swelling of glands in your face, below your chin, or around your eyes. Similarly, unexplained masses or lumps that resemble tumors warrant immediate investigation, as IgG4-RD often mimics cancer.^[3]

Other situations that call for diagnostic testing include unexplained weight loss, persistent fatigue, yellowing of the skin or eyes without fever, breathing difficulties, abdominal pain, or visual changes such as bulging eyes or double vision. Because IgG4-RD can affect nearly any organ system, symptoms vary widely depending on which organs are involved. Some patients present with acute problems like sudden pancreatitis with abdominal pain and nausea, while others develop insidious, smoldering conditions such as chronic inflammation that gradually leads to organ dysfunction.^[5]

Given that awareness of IgG4-RD remains limited among many healthcare practitioners, patients sometimes need to advocate for themselves when they experience unusual or persistent symptoms that don’t fit common diagnoses. The disease was recognized only about twenty years ago, and until recently, it didn’t even have a standardized medical code for classification. This means some doctors may not immediately consider it as a possibility when evaluating symptoms.^[13]

Classic Diagnostic Methods for Identifying IgG4-Related Disease

Diagnosing IgG4-RD requires a comprehensive approach that combines multiple types of evidence, as there is no single test that definitively confirms the condition. Doctors typically use what specialists call a “triangulation” method—bringing together clinical presentation, imaging findings, blood test results, and most importantly, tissue examination through biopsy. This multi-faceted approach is critical because IgG4-RD must be differentiated from malignant tumors, infections, and other immune-mediated diseases that can look remarkably similar.^[7][12]

Biopsy and Histopathological Examination

A biopsy—the removal of a small tissue sample for laboratory examination—is usually necessary to distinguish IgG4-RD from other causes of enlarged organs and masses. The tissue examination reveals characteristic features that are specific to this disease. Pathologists look for a dense infiltration of certain immune cells, particularly lymphocytes (a type of white blood cell) and plasma cells (immune cells that produce antibodies), with an abundance of plasma cells that specifically produce IgG4 antibodies.^[5][8]

The hallmark features that pathologists identify include storiform fibrosis, which describes a specific pattern of scar tissue formation that looks like a whorled or cartwheel pattern under the microscope. They also look for obliterative phlebitis, a condition where small veins become inflamed and eventually blocked. Additionally, the tissue often contains a variable number of eosinophils, another type of white blood cell. A key diagnostic criterion is finding that more than 40% of the IgG-producing plasma cells are specifically making IgG4, rather than other IgG subtypes.^[1][7]

However, it’s important to note that bone marrow and lymph nodes are not ideal sites for biopsy when IgG4-RD is suspected. These two locations typically lack the characteristic storiform fibrosis and obliterative phlebitis seen in other tissues, making diagnosis more difficult from these samples.^[4]

Blood Tests

Blood testing plays a supporting but important role in diagnosis. Many patients with IgG4-RD have elevated levels of serum IgG4, which can be measured through a simple blood draw. However, this finding alone is not sufficient for diagnosis because serum IgG4 levels can be normal in some patients with confirmed disease, and they can also be elevated in people who don’t have IgG4-RD. The test is helpful when elevated, but a normal result doesn’t rule out the disease.^[2][6]

Doctors may also order serum protein electrophoresis, a test that separates different proteins in the blood, which often shows a polyclonal increase in gamma globulins—meaning multiple types of antibodies are elevated, rather than just one specific type. Blood tests may reveal elevated total IgG levels and other laboratory abnormalities such as increased eosinophil counts, which are white blood cells involved in allergic and inflammatory responses.^[4]

Additional blood work includes measuring complement levels (C3 and C4), which are proteins that help regulate the immune system. Some patients may also undergo testing to rule out other conditions that can mimic IgG4-RD, such as checking for specific autoantibodies like anti-Ro/SSA and anti-La/SSB antibodies, which are associated with Sjögren disease, or looking for evidence of sarcoidosis.^[2]

Imaging Studies

Various imaging techniques help doctors visualize the extent and location of organ involvement. Computed tomography (CT) scans use X-rays to create detailed cross-sectional images of the body and are particularly useful for examining the pancreas, bile ducts, kidneys, and retroperitoneal tissues at the back of the abdomen. CT imaging can reveal characteristic patterns such as masses, organ enlargement, or abnormal tissue around blood vessels.^[5]

Magnetic resonance imaging (MRI) uses powerful magnets and radio waves to produce detailed images of soft tissues and is especially helpful for evaluating involvement of the pancreas, bile ducts, and certain other organs. Ultrasound imaging, which uses sound waves to create pictures of internal structures, is commonly employed to examine salivary glands, lacrimal glands, kidneys, and to guide biopsies of suspicious areas.^[12]

In patients with suspected involvement of the aorta or other large blood vessels, imaging can reveal circumferential thickening of the vessel walls or masses surrounding the aorta. When retroperitoneal fibrosis is present—a condition where scar tissue forms in the space behind the abdominal organs—imaging shows soft tissue masses that may compress the ureters, the tubes carrying urine from the kidneys to the bladder.^[2]

Distinguishing IgG4-RD from Similar Conditions

One of the greatest challenges in diagnosing IgG4-RD is differentiating it from conditions that appear similar. The disease can mimic various cancers, including pancreatic cancer, bile duct cancer, and lymphoma. It can also resemble other autoimmune conditions such as Sjögren disease and sarcoidosis, or infectious diseases. Several features help distinguish IgG4-RD from these other conditions.^[1]

Unlike most infectious causes of organ inflammation, IgG4-RD almost never causes fever, and patients typically don’t have elevated white blood cell counts that would suggest acute infection. The insidious, gradual onset over years rather than the acute presentation seen with infections is another distinguishing feature. When differentiating from Sjögren disease, doctors note that IgG4-RD causes prominent gland swelling but typically doesn’t produce severe dry eyes and dry mouth, which are hallmark features of Sjögren disease. Additionally, specific antibodies found in Sjögren disease are absent in IgG4-RD.^[2][6]

Sarcoidosis, another condition that can affect multiple organs, differs from IgG4-RD in several ways. Sarcoidosis shows well-formed, non-caseating granulomas on biopsy—a specific type of inflammatory nodule not seen in IgG4-RD. Sarcoidosis also commonly causes bulky lymph node enlargement in the chest, inflammation of the front part of the eye (anterior uveitis), inflammatory arthritis, and a specific skin condition called erythema nodosum, none of which are typical features of IgG4-RD.^[2]

Diagnostics for Clinical Trial Qualification

When patients are being evaluated for enrollment in clinical trials studying IgG4-RD, the diagnostic requirements often become more stringent and standardized than in routine clinical practice. Clinical trials typically have specific inclusion and exclusion criteria designed to ensure that all participants truly have the disease being studied and that the results will be meaningful and interpretable.^[9]

For entry into IgG4-RD clinical trials, patients generally must have disease that is considered active, meaning they have new or worsening signs and symptoms affecting one or more organs. The diagnosis typically needs to be confirmed through biopsy showing the characteristic histopathological features of the disease, including the dense lymphoplasmacytic infiltrate enriched with IgG4-positive plasma cells, storiform fibrosis, and obliterative phlebitis.^[11]

Blood work performed for trial qualification usually includes measurement of serum IgG4 levels to document whether they are elevated. Trials may also require baseline measurements of other markers such as complement levels, complete blood counts to check for eosinophilia or other abnormalities, and comprehensive metabolic panels to assess organ function, particularly kidney and liver function. These baseline measurements allow researchers to track how the disease and its treatment affect various body systems over time.^[4]

Imaging studies are typically required both to document which organs are involved and to measure the extent of disease at the start of the trial. This baseline imaging provides a reference point for determining whether the treatment being studied causes the disease to improve, remain stable, or progress. Common imaging modalities used in trials include CT scans, MRI, and ultrasound, depending on which organs are affected. Follow-up imaging at specified intervals during and after treatment helps researchers objectively assess treatment effectiveness.^[9]

Clinical trials often use standardized scoring systems or activity indices to objectively measure disease severity and track changes over time. These tools assess factors such as the number of organs involved, the severity of involvement in each organ, symptoms experienced by the patient, and laboratory abnormalities. Patients may need to meet certain minimum disease activity scores to qualify for enrollment, ensuring that the trial enrolls people with disease active enough to show potential improvement with treatment.^[9]

One key measure often used in trials is the “flare” rate—how often patients experience new or worsening disease activity. Trials may track time to first flare, number of flares over a specified period, and achievement of “flare-free complete remission,” meaning patients have no disease symptoms and are not experiencing new problems. The ability to discontinue corticosteroids while maintaining disease control is another important outcome that trials frequently measure, given the significant side effects these medications cause.^[9][11]

Exclusion criteria for trials typically screen out patients who have conditions that could interfere with interpreting results or who might be at increased risk from the experimental treatment. This might include excluding patients with certain infections, other autoimmune diseases, or those who have received specific treatments within a certain time frame before trial enrollment. The goal is to create a study population where the effects of the treatment can be clearly observed and attributed to the medication being tested rather than to other factors.^[9]